MET and gastric cancer: To the best of our knowledge, this is the first study to evaluate the overexpression of MET as a risk factor for the presence of PD-L1 positivity in gastric cancer tissue and its relevance as a reliable prognostic marker for PD-L1/MET co-expression in gastric cancers.